Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China

Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.009 · Cited by 3,809

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,127

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Wu, A., Peng, Y., Huang, B., Ding, X. L., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,386

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678

The Novel Coronavirus Originating in Wuhan, China

Phelan, A., Katz, R., & Gostin, L. O. (2020) · JAMA · doi:10.1001/jama.2020.1097 · Cited by 1,210

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Whitt, M. A. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.08.006 · Cited by 431

Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study

Ai, J., Zhang, Y., Zhang, H., Zhang, Q., Fu, Z., Lin, K., Song, J., Zhao, Y., Fan, M., Wang, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2025746 · Cited by 40

Evolution, Interspecies Transmission, and Zoonotic Significance of Animal Coronaviruses

Parkhe, P., & Verma, S. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.719834 · Cited by 40

A second functional furin site in the SARS-CoV-2 spike protein

Zhang, Y., Zhang, L., Wu, J., Yu, Y., Liu, S., Li, T., Li, Q., Ding, R., Wang, H., Nie, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2014284 · Cited by 42

Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern

Yu, X., Wei, D., Xu, W., Liu, C., Guo, W., Li, X., Tan, W., Liu, L., Zhang, X., Qu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29477-0 · Cited by 38

Engineering photonics solutions for COVID-19

Soler, M., Scholtz, A., Zeto, R., & Armani, A. M. (2020) · APL Photonics · doi:10.1063/5.0021270 · Cited by 41

Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay

López, E., Haycroft, E. R., Adair, A., Mordant, F. L., O’Neill, M. T., Pymm, P., Redmond, S. J., Lee, W. S., Gherardin, N. A., Wheatley, A. K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150012 · Cited by 38

Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera

Kruglova, N., Siniavin, A., Gushchin, V., & Mazurov, D. (2021) · Viruses · doi:10.3390/v13061133 · Cited by 37

Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile

Beltrán-Pavez, C., Riquelme-Barrios, S., Oyarzún-Arrau, A., Gaete-Argel, A., González‐Stegmaier, R., Cereceda, K., Aguirre, A., Travisany, D., Palma-Véjares, R., Barriga, G. P., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe6855 · Cited by 37

Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses

Nie, J., Li, Q., Zhang, L., Cao, Y., Zhang, Y., Li, T., Wu, J., Liu, S., Zhang, M., Zhao, C., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00256-3 · Cited by 42

Key mutations in the spike protein of SARS‐CoV‐2 affecting neutralization resistance and viral internalization

Wang, Q., Ye, S., Zhou, Z., Song, A., Zhu, X., Peng, J., Liang, R., Yang, C., Yu, X., Huang, X., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28407 · Cited by 37

Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis

Hou, Y., Ge, S., Li, X., Wang, C., He, H., & He, L. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109420 · Cited by 36

Expression of SARS-CoV-2 surface glycoprotein fragment 319–640 in E. coli, and its refolding and purification

Fitzgerald, G. A., Komarov, A. M., Kaznadzey, A., Mazo, I. A., & Kireeva, M. L. (2021) · Protein Expression and Purification · doi:10.1016/j.pep.2021.105861 · Cited by 36

Polymersomes as Stable Nanocarriers for a Highly Immunogenic and Durable SARS-CoV-2 Spike Protein Subunit Vaccine

Lam, J. H., Khan, A. K., Cornell, T., Chia, T. W., Dress, R. J., Yeow, W. W. W., Mohd-Ismail, N. K., Venkataraman, S., Ng, K. T., Tan, Y., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c01243 · Cited by 36

Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants

Zhang, J. Z., Yeh, A. H.-W., Walls, A. C., Wicky, B. I. M., Sprouse, K. R., VanBlargan, L. A., Treger, R. S., Quijano‐Rubio, A., Pham, M. N., Kraft, J. C., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01280-8 · Cited by 37

The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination

Benschop, R. J., TUTTLE, J. L., Zhang, L., Poorbaugh, J., Kallewaard, N. L., Vaillancourt, P., Crisp, M., Trinh, T. N. V., Freitas, J. J., Beasley, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3041 · Cited by 38

Oroxylin A is a severe acute respiratory syndrome coronavirus 2‐spiked pseudotyped virus blocker obtained from Radix Scutellariae using angiotensin‐converting enzyme II /cell membrane chromatography

Gao, J., Ding, Y., Wang, Y., Liang, P., Zhang, L., & Liu, R. (2021) · Phytotherapy Research · doi:10.1002/ptr.7030 · Cited by 35

Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay

Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E. J., Manguiat, K., Lindsay, L. R., Wood, H., DREBOT, M. A., Dibernardo, A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab220 · Cited by 35

Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test

Embregts, C. W. E., Verstrepen, B. E., Langermans, J. A. M., Böszörményi, K. P., Sikkema, R. S., de Vries, R. D., Hoffmann, D., Wernike, K., Smit, L. A. M., Zhao, S., et al. (2021) · One Health · doi:10.1016/j.onehlt.2021.100313 · Cited by 35

The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies

Durdağı, S., Avşar, T., Orhan, M. D., Serhatlı, M., Balcıoğlu, B. K., Öztürk, H. Ü., Kayabölen, A., Çetin, Y., Aydınlık, Ş., Onder, T. B., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.014 · Cited by 35

Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2

Goméni, R., Xu, T., Gao, X., & Bressolle, F. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09690-4 · Cited by 34

Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development

Huang, S.-W., Tai, C.-H., Hsu, Y.-M., Cheng, D., Hung, S.-J., Chai, K. M., Wang, Y., & Wang, J. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.06.003 · Cited by 34

Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles

Miyakawa, K., Jeremiah, S. S., Ohtake, N., Matsunaga, S., Yamaoka, Y., Nishi, M., Morita, T., Saji, R., Nishii, M., Kimura, H., et al. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa047 · Cited by 34

Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy

Ma, M., Shi, D., Li, Y., Hong, W., Lai, D., Xue, J., Jiang, H., Zhang, H., Qi, H., Meng, Q., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00309-7 · Cited by 34

Potential drug discovery for COVID-19 treatment targeting Cathepsin L using a deep learning-based strategy

Yang, W., Li, Q., Sun, J., Tan, S. H., Tang, Y.-H., Zhao, M., Li, Y., Cao, X., Zhao, J., & Yang, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.05.023 · Cited by 34

Profiling and characterization of SARS-CoV-2 mutants’ infectivity and antigenicity

Wang, L., Wang, L., & Zhuang, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00302-8 · Cited by 34

Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2

Müller, K., Girl, P., von Buttlar, H., Dobler, G., & Wölfel, R. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114122 · Cited by 33

Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2

Zhu, L., Deng, Y., Zhang, R.-R., Cui, Z., Sun, C.-Y., Fan, C., Xing, X., Huang, W., Chen, Q., Zhang, N.-N., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa297 · Cited by 34

Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay

Tolah, A. M., Sohrab, S. S., Tolah, K. M., Hassan, A. M., El-Kafrawy, S. A., & Azhar, E. I. (2021) · Diagnostics · doi:10.3390/diagnostics11060994 · Cited by 34

A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays

Gilboa, T., Cohen, L., Cheng, C., Lazarovits, R., Uwamanzu‐Nna, A., Han, I., Griswold, K., Barry, N., Thompson, D. B., Kohman, R. E., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202110702 · Cited by 34

Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants

Wang, Q., Yang, C., Yin, L., Sun, J., Wang, W., Li, H., Zhang, Z., Chen, S. E., Liu, B., Liu, Z., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01423-6 · Cited by 34

Alpha-1-antitrypsin and its variant-dependent role in COVID-19 pathogenesisPreprint

Stevens, C. S., Oguntuyo, K. Y., Kowdle, S., Brambilla, L., Haas, G. D., Gowlikar, A., Siddiquey, M. N. A., Schilke, R. M., Woolard, M. D., Zhang, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.14.248880 · Cited by 33

COVID‐19 vaccines: Knowing the unknown

Lv, H., Wu, N. C., & Mok, C. K. P. (2020) · European Journal of Immunology · doi:10.1002/eji.202048663 · Cited by 32

A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

Miao, X., Luo, Y., Huang, X., Lee, S. M.-Y., Yuan, Z., Tang, Y., Chen, L., Wang, C., Wu, F., Xu, Y.-F., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1804241 · Cited by 33

Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses

Wang, Y.-D., Liu, M., Shen, Y., Ma, Y., Li, X., Zhang, Y., Liu, M., Yang, X., Chen, J., Yan, R., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00401-6 · Cited by 32

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2

Han, X., Wang, Y., Li, S., Hu, C., Li, T., Gu, C., Wang, K., Shen, M., Wang, J., Hu, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653189 · Cited by 32

Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates

He, Q., Mao, Q., Peng, X., He, Z., Lu, S., Zhang, J., Gao, F., Bian, L., An, C., Yu, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00926-y · Cited by 31

Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?

Xi, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00310-8 · Cited by 30

Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies

Chen, S. E., Zhang, Z., Wang, Q., Yang, Q., Yin, L., Ning, L., Chen, Z., Tang, J., Deng, W., He, P., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01906-0 · Cited by 30

An evolving approach to the laboratory assessment of COVID‐19

Lu, H., Stratton, C. W., & Tang, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25954 · Cited by 30

COVID-19 vaccines: progress and understanding on quality control and evaluation

Mao, Q., Xu, M., He, Q., Li, C., Meng, S., Wang, Y., Cui, B., Liang, Z., & Wang, J. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00621-4 · Cited by 29

Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation

Chen, H.-Y., Huang, C., Tian, L., Huang, X., Zhang, C., Llewellyn, G. N., Rogers, G. L., Andresen, K., O’Gorman, M. R. G., Chen, Y., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00966-21 · Cited by 31

Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019

Salazar–García, M., Acosta-Contreras, S., Martinez, G. R., Cruz‐Rangel, A., Flores-Alanis, A., Patiño‐López, G., & Luna-Pineda, V. M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.817200 · Cited by 29

Designer DNA nanostructures for viral inhibition

Ren, S., Fraser, K., Kuo, L., Chauhan, N., Adrian, A. T., Zhang, F., Linhardt, R. J., Kwon, P. S., & Wang, X. (2022) · Nature Protocols · doi:10.1038/s41596-021-00641-y · Cited by 29

Innate and Adaptive Immunity of Murine Neural Stem Cell-Derived piRNA Exosomes/Microvesicles against Pseudotyped SARS-CoV-2 and HIV-Based Lentivirus

Yu, B., Ikhlas, S., Ruan, C., Zhong, X., & Cai, D. (2020) · iScience · doi:10.1016/j.isci.2020.101806 · Cited by 28

Virus‐Free and Live‐Cell Visualizing SARS‐CoV‐2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors

Zhang, Y., Wang, S., Wu, Y., Hou, W., Yuan, L., Shen, C., Wang, J., Ye, J., Zheng, Q., Ma, J., et al. (2020) · Small Methods · doi:10.1002/smtd.202001031 · Cited by 28

Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy

Gontu, A., Srinivasan, S., Salazar, E., Nair, M. S., Nissly, R. H., Greenawalt, D. I., Bird, I. M., Herzog, C. M., Ferrari, M. J., Poojary, I. B., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01813-y · Cited by 28

Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay

Murray, M. J., McIntosh, M., Atkinson, C. E., Mahungu, T. W., Wright, E., Chatterton, W., Gandy, M., & Reeves, M. B. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.03.010 · Cited by 28

IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

Vandergaast, R., Carey, T. S., Reiter, S., Lathrum, C., Lech, P. J., Gnanadurai, C. W., Haselton, M., Buehler, J., Narjari, R., Schnebeck, L., et al. (2021) · mSphere · doi:10.1128/msphere.00170-21 · Cited by 27

Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19

Sun, C., Jan, J., Wang, I.-H., Ma, H., Ko, H., Wu, P., Kuo, T.-J., Liao, H.-N., Lan, Y.-H., Sie, Z., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009758 · Cited by 28

Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma

Mishra, N., Kumar, S., Singh, S., Bansal, T., Jain, N., Saluja, S., Kumar, R., Bhattacharyya, S., Palanichamy, J. K., Mir, R. A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009958 · Cited by 27

Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity

Jia, L., Weng, S., Wu, J., Tian, X., Zhang, Y., Wang, X., Wang, J., Yan, D., Wang, W., Fang, F., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2117503 · Cited by 28

Rapid biosensing SARS-CoV-2 antibodies in vaccinated healthy donors

Bian, S., Shang, M., & Sawan, M. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114054 · Cited by 27

Detection of neutralizing antibodies against multiple SARS-CoV-2 strains in dried blood spots using cell-free PCR

Danh, K., Karp, D. G., Singhal, M., Tankasala, A., Gebhart, D., Cortez, F. D. J., Tandel, D., Robinson, P. V., Seftel, D., Stone, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31796-1 · Cited by 27

The role of pseudotype neutralization assays in understanding SARS CoV-2

Cantoni, D. M., Neto, M. M., & Temperton, N. J. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab005 · Cited by 27

Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19

Xu, K., An, Y., Li, Q., Huang, W., Han, Y., Zheng, T., Fang, F., Liu, H., Liu, C., Gao, P., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1959270 · Cited by 25

Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells

Caohuy, H., Eidelman, O., Chen, T., Liu, S., Yang, Q., Bera, A., Walton, N. I., Wang, T. T., & Pollard, H. B. (2021) · Scientific Reports · doi:10.1038/s41598-021-01690-9 · Cited by 27

Rapid test to assess the escape of SARS-CoV-2 variants of concern

Heggestad, J. T., Britton, R. J., Kinnamon, D., Wall, S. A., Joh, D. Y., Hucknall, A., Olson, L. B., Anderson, J. G., Mazur, A., Wolfe, C. R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abl7682 · Cited by 25

SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets

Shivshankar, P., Karmouty‐Quintana, H., Mills, T., Doursout, M., Wang, Y., Czopik, A. K., Evans, S. E., Eltzschig, H. K., & Yuan, X. (2022) · Inflammation · doi:10.1007/s10753-022-01656-7 · Cited by 28

Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China

Han, X., Yu, X., Han, Y., Fang, Q., Shen, C., Liu, H., Wang, P., Wang, Y., & Li, X. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s353127 · Cited by 25

A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept

Cruz-Cárdenas, J. A., Gutiérrez, M., López-Arredondo, A., Castañeda‐Delgado, J. E., Rojas‐Martínez, A., Nakamura, Y., Enciso‐Moreno, J. A., Palomares, L. A., & Brunck, M. E. G. (2022) · Scientific Reports · doi:10.1038/s41598-022-22921-7 · Cited by 28

Efficient inactivation of the contamination with pathogenic microorganisms by a combination of water spray and plasma-activated air

Guo, L., Zhao, P., Jia, Y., Li, T., Huang, L., Wang, Z., Liu, D., Hou, Z., Zhao, Y., Zhang, L., et al. (2022) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2022.130686 · Cited by 25

The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86

Stuart, D., Liu, C., Das, R., Dijokaite-Guraliuc, A., Zhou, D., Duyvesteyn, H. M. E., Mentzer, A. J., Supasa, P., Selvaraj, M., Ritter, T. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46982-6 · Cited by 25

Dual-Fluorescence Labeling Pseudovirus for Real-Time Imaging of Single SARS-CoV-2 Entry in Respiratory Epithelial Cells

Ma, Y., Mao, G., Wu, G., Chen, M., Qin, F., Zheng, L., & Zhang, X. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c03897 · Cited by 24

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together

Zhang, L., Poorbaugh, J., Dougan, M. L., Chen, P., Gottlieb, R., Huhn, G. D., Beasley, S., Daniels, M., Trinh, T. N. V., Crisp, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790469 · Cited by 25

Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling

Ai, J., Guo, J., Zhang, H., Zhang, Y., Yang, H., Lin, K., Song, J., Fu, Z., Fan, M., Zhang, Q., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00480-5 · Cited by 25

A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients

Luo, Y. R., Yun, C., Chakraborty, I., Wu, A. H. B., & Lynch, K. L. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00193-21 · Cited by 24

Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays

Virtanen, J. M. E., Uusitalo, R., Korhonen, E. M., Aaltonen, K., Smura, T., Kuivanen, S. H., Pakkanen, S. H., Mero, S., Patjas, A., Riekkinen, M., et al. (2021) · Viruses · doi:10.3390/v13060996 · Cited by 25

Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid

Li, L., Long, J., Sang, Y., Wang, X., Zhou, X., Pan, Y., Cao, Y., Huang, H., Yang, Z., Yang, J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.023 · Cited by 24

Clinical analysis and pluripotent stem cells-based model reveal possible impacts of ACE2 and lung progenitor cells on infants vulnerable to COVID-19

Zhang, Z., Guo, L., Lü, X., Zhang, C., Huang, L., Wang, X., Duan, F., Liang, H., Chen, P., Zeng, L., et al. (2020) · Theranostics · doi:10.2139/ssrn.3602441 · Cited by 23

An optimized and robust SARS-CoV-2 pseudovirus system for viral entry research

Yang, P., Yang, Y., Wu, Y., Huang, C., Ding, Y., Wang, X., & Wang, S. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114221 · Cited by 23

Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods

Ndzouboukou, J. B., Zhang, Y., & Fan, X. (2021) · Current Medical Science · doi:10.1007/s11596-021-2470-7 · Cited by 23

Baculovirus-Free SARS-CoV-2 Virus-like Particle Production in Insect Cells for Rapid Neutralization Assessment

Jaron, M., Lehky, M., Zarà, M., Zaydowicz, C. N., Lak, A., Ballmann, R., Heine, P. A., Wenzel, E. V., Schneider, K.-T., Bertoglio, F., et al. (2022) · Viruses · doi:10.3390/v14102087 · Cited by 23

Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay

D’Apice, L., Trovato, M., Gramigna, G., Colavita, F., Francalancia, M., Matusali, G., Meschi, S., Lapa, D., Bettini, A., Mizzoni, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.981693 · Cited by 23

Multi-omics for COVID-19: driving development of therapeutics and vaccines

Guo, M., Xiong, M., Peng, J., Guan, T., Su, H., Huang, Y., Yang, C., Li, Y., Boraschi, D., Pillaiyar, T., et al. (2023) · National Science Review · doi:10.1093/nsr/nwad161 · Cited by 24

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant

Yu, X., Qi, X., Cao, Y. X., Li, P., Li, L., Wang, P., Feng, Y., Yang, J., Wei, H., Guo, L., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2044271 · Cited by 23

Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants

Sun, H., Xu, J., Zhang, G., Han, J., Hao, M., Chen, Z., Fang, T., Chi, X., & Yu, C. (2022) · Viruses · doi:10.3390/v14061332 · Cited by 24

Inhaled non-viral delivery systems for RNA therapeutics

Huang, C., Li, H., Duan, X., Zhang, P., Qi, S., Du, J., Song, X., Tong, A., & Yu, G. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.033 · Cited by 21

Latex Microsphere-Based Bicolor Immunochromatography for Qualitative Detection of Neutralizing Antibody against SARS-CoV-2

Liang, Z., Peng, T., Jiao, X., Zhao, Y. C., Xie, J., Jiang, Y., Meng, B., Fang, X. Z., Yu, X., & Dai, X. (2022) · Biosensors · doi:10.3390/bios12020103 · Cited by 22

Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5

Wang, Y., Yan, A., Song, D., Dong, C., Rao, M., Gao, Y., Qi, R., Ma, X., Wang, Q., Xu, H., et al. (2023) · Cell Discovery · doi:10.1038/s41421-022-00509-9 · Cited by 21

Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2

Chen, C., Liang, J., Hu, H., Li, X., Wang, L., & Wang, Z. (2023) · Analytical Biochemistry · doi:10.1016/j.ab.2023.115199 · Cited by 22

Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults

Zhang, H., Xu, N., Xu, Y. S., Qin, P., Dai, R., Xu, B., Wang, S., Ding, L., Fu, J., Zhang, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40489-2 · Cited by 23

Exosomes/microvesicles target SARS-CoV-2 via innate and RNA-induced immunity with PIWI-piRNA system

Ikhlas, S., Usman, A., Kim, D., & Cai, D. (2021) · Life Science Alliance · doi:10.26508/lsa.202101240 · Cited by 21

Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 InfectionPreprint

Liu, X., Gao, F., Gou, L., Chen, Y., Gu, Y., Ao, L., Shen, H., Hu, Z., Guo, X., & Gao, W. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.03.074914 · Cited by 21

Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination

Chen, Y., Zhu, L., Huang, W., Tong, X., Wu, H., Tao, Y., Tong, B., Huang, H., Chen, J., Zhao, X., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1942227 · Cited by 20

Using cold atmospheric plasma treated-air for COVID-19 disinfection in cold-chain environment

Zhang, H., Chen, M., Huang, L., Guo, L., Xu, S., Zhang, J., Wang, X., Wang, Z., Liu, D., Kong, M. G., et al. (2021) · Journal of Physics D Applied Physics · doi:10.1088/1361-6463/ac13f7 · Cited by 20

SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications

Yuan, L., Tang, Q., Zhu, H., Guan, Y., Cheng, T., & Xia, N. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1976598 · Cited by 20

Durability of Neutralization Against Omicron Subvariants after Vaccination and Breakthrough Infection

Zhu, K.-L., Jiang, X., Zhan, B., Wang, X., Xia, X., Cao, G.-P., Sun, W., Huang, P., Zhang, J., Gao, Y.-L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2023.112075 · Cited by 20

Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability

Gorman, J., Cheung, C. S., Duan, Z., Ou, L., Wang, M., Chen, X., Cheng, C., Biju, A., Sun, Y., Wang, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44534-y · Cited by 20

Pseudovirus-Based Systems for Screening Natural Antiviral Agents: A Comprehensive Review

Trischitta, P., Tamburello, M. P., Venuti, A., & Pennisi, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105188 · Cited by 20

Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19

Cao, J., Liu, Y., Zhou, M., Dong, S., Hou, Y., Jia, X., Lan, X., Zhang, Y., Guo, J., Xiao, G., et al. (2022) · Viruses · doi:10.3390/v14020353 · Cited by 20

Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Pan, H., Liu, J., Huang, B., Li, G., Chang, X., Liu, Y., Wang, W., Chu, K., Zhu, D., Wu, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab627 · Cited by 19

Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model

Liu, K., Gong, Y., Huang, C., Huang, P.-N., Yu, K.-Y., Lee, H.-C., Lee, S.-C., Chiang, H.-J., Kung, Y.-A., Lin, Y., et al. (2022) · mSphere · doi:10.1128/msphere.00883-21 · Cited by 19

The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies

Zhang, S., Gao, C., Das, T., Luo, S., Tang, H., Yao, X., Cho, C. Y., Lv, J., Maravillas, K., Jones, V. S., et al. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113244 · Cited by 19

Evaluation of Two Rapid Lateral Flow Tests and Two Surrogate ELISAs for the Detection of SARS-CoV-2 Specific Neutralizing Antibodies

Girl, P., Zwirglmaier, K., von Buttlar, H., Wölfel, R., & Müller, K. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.820151 · Cited by 19

Resveratrol Inhibits Pseudorabies Virus Replication by Targeting IE180 Protein

Chen, X., Song, X., Li, L., Chen, Y., Jia, R., Zou, Y., Wan, H., Zhao, L., Tang, H., Lv, C., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.891978 · Cited by 19

SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review

Sun, Y., Huang, W., Xiang, H., & Nie, J. (2024) · Vaccines · doi:10.3390/vaccines12050554 · Cited by 20

Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors

Xu, T., Meng, J., Cheng, W., Liu, J., Chu, J., Zhang, Q., Ma, N., Bai, L., & Guo, Y. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116838 · Cited by 19

Diagnostic testing for SARS-CoV-2/COVID19

Spearman, P. W. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000972 · Cited by 21

Recent advances in the diagnosis of COVID-19: a bird’s eye view

Sharma, B., Shahanshah, M. F. H., Gupta, S., & Gupta, V. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1874354 · Cited by 18

Evaluation of the performance of SARS‐CoV‐2 antibody assays for a longitudinal populationbased study of COVID‐19 spread in St. Petersburg, Russia

Барчук, А. А., Shirokov, D., Sergeeva, M. V., Турсун-заде, Р. Т., Dudkina, O., Tychkova, V., Barabanova, L., Skougarevskiy, D., & Danilenko, D. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27126 · Cited by 18

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0394-5 · Cited by 427

Detection of Neutralizing Antibodies in Serum Samples Using a SARS‐CoV‐2 Pseudotyped Virus Assay

Ferrero, S., Batto, M. V., Gatto, M. I., Dimase, F., & Helguera, G. F. (2024) · Current Protocols · doi:10.1002/cpz1.70025

Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay

Tolah, A. M., Sohrab, S. S., Tolah, K. M., Hassan, A. M., El-Kafrawy, S. A., & Azhar, E. I. (2021) · Diagnostics · doi:10.3390/diagnostics11060994 · Cited by 34

Design and Development of a Pseudotyped-lentivirus for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hassannia, H., Enderami, S. E., Mansour, R. N., Eftekhary, M., Abazari, M., & Salarinia, R. (2023) · DOAJ (DOAJ: Directory of Open Access Journals)

Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2

Balinsky, C. A., Jani, V., Sun, P., Williams, M., Defang, G. N., & Porter, K. R. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2111-0_21 · Cited by 5